Your AI-Trained Oncology Knowledge Connection!
Better progression-free survival, as well as improved responses, were seen when lenvatinib was combined with either pembrolizumab or everolimus versus standard-of-care sunitinib in the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting.
In patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors, enfortumab vedotin induced the highest response rates seen with any regimen in this setting.
In non-muscle invasive bladder cancer carcinoma in-situ that is not responsive to BCG alone, the addition of N-803 leads to efficacy while maintaining safety.
Patients with metastatic renal cell carcinoma and brain metastases showed significant intracranial and extracranial responses with cabozantinib use.
Compared with androgen-deprivation therapy alone, patients with metastatic castration-sensitive prostate cancer had better outcomes when apalutamide was added to systemic therapy.
Adjuvant therapy with nivolumab was superior to placebo for improving disease-free survival in patients with muscle-invasive urothelial carcinoma.
Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy.
Compared against sunitinib, nivolumab plus cabozantinib induced better outcomes in patients with advanced renal cell carcinoma and these results were seen in patients with and without sarcomatoid features.
The potential to identify occult prostate cancer and accurately characterize disease burden was observed with the novel prostate specific membrane antigen (PSMA)–targeted radiopharmaceutical for PET imaging technique.
Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.
Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed additional clinical evidence.
As third- or fourth-line therapy for patients with metastatic RCC, tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity compared with sorafenib.
Darolutamide still has a favorable safety profile with prolonged treatment among patients with nonmetastatic castration-resistant prostate cancer.
First-line treatment with nivolumab plus cabozantinib demonstrated health-related quality of life benefits in patients with advanced renal cell carcinoma.
“Based on these findings, patients who received lenvatinib 18 mg starting dose had better quality of life and less severe symptoms than those who received lenvatinib 14 mg starting dose,” said Cristiane Decat Bergerot, PhD, MS, BS.
For patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy, abiraterone acetate and prednisone plus the addition of apalutamide reduced the risk of radiographic progression or death by 30%.
Avelumab plus best supportive care as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy.
Antitumor activity and a tolerable safety profile were observed for VERU-111, a novel tubulin inhibitor, to treat patients with metastatic castration-resistant prostate cancer who previously failed an androgen receptor–targeting agent.
Improvement in overall survival (OS) for patients with metastatic non–clear cell renal cell carcinoma (RCC) was linked with first-line treatment using immune checkpoint inhibitor–based regimens versus select targeted therapies
No significant activity or favorable toxicity profile was found with sapanisertib when treating patients with refractory mRCC regardless of mTOR or PTEN status.
High response rates with novel eganelisib plus PD-1 inhibition is reported in patients with metastatic urothelial carcinoma, especially those with low PD-L1 expression.
Based on an exploratory analysis of a phase 2 trial, lenvatinib plus everolimus appears to be an acceptable treatment option for patients receiving prior immunotherapy for clear cell renal cell carcinoma.
Despite a high rate of hematologic toxicity, combined low-dose gemcitabine (Gemzar), paclitaxel, and sorafenib (Nexavar) showed promise as a well-tolerated salvage therapy in a small group of patients with cisplatin-resistant urothelial cancer.
BRCA mutations and co-occurring gene alterations in prostate cancer suggest that some patients might benefit from oral poly (ADP-ribose) polymerase (PARP) inhibitors.
